StockData
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Cullinan Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$13.98+1.05 (+8.12%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Cullinan Therapeutics, Inc. revenue by segment

No segment breakdown reported

Cullinan Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.